Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026
Filed with Euronext · · 4 pages · French and English
Earlier from Inventiva
- Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
- Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH
- Inventiva Appoints Chris Benecchi as Chief Operating Officer
- Inventiva nomme Chris Benecchi au poste de Chief Operating Officer
- Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Later from Inventiva
- Inventiva to Present Multiple Abstracts at Paris MASH 2026
- Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
- Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
- Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Follow Inventiva into a list and get an email when it puts out news.
Follow Inventiva